Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Balestro, F. Lunardi, E. Rossi, N. Nannini, G. Marulli, M. Loy, F. Rea, F. Calabrese (Padova, Italy). Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF). Eur Respir J 2011; 38: Suppl. 55, 4861

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Morphometric characteristic of pulmonary artery in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 The influence of pulmonary disease on ventricular diastolic disfunction in COPD and idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 98s Year: 2002 The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Morphological and immunohistochemical characteristics of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Arterial stiffness and endothelial dysfunction in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015